These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11488711)

  • 1. Spironolactone-induced hepatitis.
    Thai KE; Sinclair RD
    Australas J Dermatol; 2001 Aug; 42(3):180-2. PubMed ID: 11488711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug reaction with eosinophilia and systemic symptoms caused by spironolactone: Case report.
    Fernandes RA; Regateiro FS; Faria E; Martinho A; Gonçalo M; Todo-Bom A
    Contact Dermatitis; 2018 Oct; 79(4):255-256. PubMed ID: 30009386
    [No Abstract]   [Full Text] [Related]  

  • 3. Eplerenone relieves spironolactone-induced painful gynaecomastia in patients with decompensated hepatitis B-related cirrhosis.
    Mimidis K; Papadopoulos V; Kartalis G
    Scand J Gastroenterol; 2007 Dec; 42(12):1516-7. PubMed ID: 17907040
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rhinorrhea as side-effect of spironolactone].
    Ayerbe García-Monzón L; Herrero Hernández S; González López E; Alcaraz Borrajo M
    Aten Primaria; 2004 Feb; 33(3):164. PubMed ID: 14987504
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone hepatitis in primary hyperaldosteronism.
    Shuck J; Shen S; Owensby L; Leftik M; Cucinell S
    Ann Intern Med; 1981 Dec; 95(6):708-10. PubMed ID: 7305153
    [No Abstract]   [Full Text] [Related]  

  • 7. Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study.
    Grandhi R; Alikhan A
    Dermatology; 2017; 233(2-3):141-144. PubMed ID: 28472793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effect of spironolactone on androgenic alopecia.
    Adamopoulos DA; Karamertzanis M; Nicopoulou S; Gregoriou A
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):759-60. PubMed ID: 9497885
    [No Abstract]   [Full Text] [Related]  

  • 9. Allergic contact dermatitis from spironolactone.
    Corazza M; Strumìa R; Lombardi AR; Virgili A
    Contact Dermatitis; 1996 Dec; 35(6):365-6. PubMed ID: 9118635
    [No Abstract]   [Full Text] [Related]  

  • 10. Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy.
    Adenuga P; Summers P; Bergfeld W
    J Am Acad Dermatol; 2012 Sep; 67(3):e121-3. PubMed ID: 22890743
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of spironolactone therapy in women with acne.
    Lubbos HG; Hasinski S; Rose LI; Pollock J
    Arch Dermatol; 1998 Sep; 134(9):1162-3. PubMed ID: 9762041
    [No Abstract]   [Full Text] [Related]  

  • 13. Eplerenone and chronic heart failure. No comparison with spironolactone.
    Prescrire Int; 2013 Jun; 22(139):148-9. PubMed ID: 23866347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
    Berry C; McMurray JJ
    Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone treatment for dermatologic indications is not associated with hypotension in a single-center retrospective study.
    Hill RC; Wang Y; Shaikh B; Ong M; Christos PJ; Lipner SR
    J Am Acad Dermatol; 2024 Jun; 90(6):1245-1247. PubMed ID: 38483433
    [No Abstract]   [Full Text] [Related]  

  • 16. ACP Journal Club. Trimethoprim-sulfamethoxazole was linked to sudden death in older patients using spironolactone.
    Ananthakrishnan S
    Ann Intern Med; 2015 Jun; 162(12):JC13. PubMed ID: 26075778
    [No Abstract]   [Full Text] [Related]  

  • 17. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
    Hu Y; Carpenter JP; Cheung AT
    Anesth Analg; 2002 Jul; 95(1):39-41, table of contents. PubMed ID: 12088939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone May be a Cause of Hormonally Associated Vestibulodynia and Female Sexual Arousal Disorder.
    Mitchell L; Govind V; Barela K; Goldstein AT
    J Sex Med; 2019 Sep; 16(9):1481-1483. PubMed ID: 31351850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
    Lindhardt M; Persson F; Oxlund C; Jacobsen IA; Zürbig P; Mischak H; Rossing P; Heerspink HJL
    Nephrol Dial Transplant; 2018 Feb; 33(2):296-303. PubMed ID: 28064163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.